TPS5639 Background: Treatment options for persistent, metastatic, or recurrent endometrial
cancer continues to evolve as we learn more about the molecular landscape of this disease …

Objectives Patients with advanced or recurrent EC have few treatment options and succumb
to the cancer rapidly. Approximately 40% of patients with ER-positive, endometrial cancer …

Endometrial cancer (EC) is the most common gynecologic cancer in Europe and its
prevalence is increasing. EC includes a biological and clinical heterogeneous group of …

Background PI3K pathway activation is common in endometrial cancer. We evaluated the
safety and efficacy of the dual PI3K/mTOR inhibitor, LY3023414, in patients with advanced …

Purpose NRG Oncology conducted a phase II trial to assess the antitumor activity and
tolerability of copanlisib, a selective inhibitor of PIK3CA, in persistent or recurrent …

Background Beyond first line treatment with platinum-based chemotherapy, there is lack of
effective and well tolerated regimens for patients with metastatic endometrial carcinomas …

Background: Lenvatinib and pembrolizumab (LEN+ PEM) combination therapy received
accelerated approval by FDA in September 2019 (standard approval July 2021) for the …

Objective Patients with endometrial carcinoma who progress after first-line chemotherapy
have a poor prognosis. Phosphoinositide 3-kinase (PI3K) inhibitors are investigational …

Objectives Managing advanced endometrial cancer (EC) after platinum therapy remains a
challenge. Retifanlimab is an investigational humanized monoclonal antibody against …

Hong Kong, Shanghai & Florham Park, NJ—Thursday, July 20, 2023: HUTCHMED (China)
Limited (“HUTCHMED”)(Nasdaq/AIM:​ HCM; HKEX:​ 13) today announces that the Center …